Japanese journal of clinical oncology
-
Jpn. J. Clin. Oncol. · Feb 2007
Rectal morbidity following I-125 prostate brachytherapy in relation to dosimetry.
To investigate rectal morbidity after I-125 prostate brachytherapy and to analyze predictive factors of rectal morbidity. ⋯ Manifestations of rectal morbidity are acceptable events after I-125 prostate brachytherapy. Rectal dose-volume histogram for the brachytherapy is a predictive method for assessing the risk of developing grade 2 rectal bleeding. Delivery of the rectal dose should not exceed 160 Gy in order to avoid rectal complications.
-
Jpn. J. Clin. Oncol. · Feb 2007
Initial experience with the quality assurance program of radiation therapy on behalf of Japan Radiation Oncology Group (JAROG).
We evaluated the efficacy of our quality assurance (QA) program of radiation therapy (RT) in a prospective phase II study. This is the first description of the experience of the Japan Radiation Oncology Group (JAROG) with this program. ⋯ This is the first report with regard to the QA program in MALT lymphoma. We demonstrated that our QA program was simple and inexpensive. We also confirmed that the radiation oncologists in Japan adhered closely to the protocol guidelines.